Latest filing published 13 Nov 2023 for Intercept Pharmaceuticals, INC., €403k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Jared Freedberg is a declared insider of Intercept Pharmaceuticals, Inc. (senior executive), with filings sourced from SEC (Form 4). Between 27 January 2022 and 8 November 2023, the trades on record add up to 12 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
On 13 November 2023 came the latest disclosure, a transaction for €403k in Intercept Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations